Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 205-212

  Hashiguchi, Yasunori ^a   Tsuda, Hiroshi ^a   Bandera, Christina A ^b   Nishimura, Sadako ^a   Inoue, Takeshi ^a   Kawamura, Naohi ^a   Berkowitz, Ross S ^b   Mok, Samuel C ^b  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endometrioid endometrial cancer; Osteopontin; Ovarian endometrioid cancer

Indexed keywords

DNA; MESSENGER RNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CELL LABELING; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DNA DETERMINATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OSTEOPONTIN; OVARIAN NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA, NEOPLASM; SIALOGLYCOPROTEINS;

EID: 33646887347     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:205     Document Type: Article

References (13)

1. William JH, Carlos AP, Robert CY. Principles and practice of gynecologic oncology. 3rd ed. Lippincott Williams & Wilkins, Philadelphia, 2000, pp. 917-930, 995-1006.
2. Zwart J, Geisler JP, GeislerHE. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol 1998; 19: 225.
3. Kim JH, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
4. Liaw L, et al. The adhesive and migratory effects of osteopontin are mediated by distinct cell surface integrins. J Clin Invest 1995; 95: 713-724.
5. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512.
6. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-5215.
7. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998; 29: 1250-1254.
8. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100.
9. Brown LF, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-623.
10. Rudland PS, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-3427.
11. Casson AG, et al. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739-745.
12. Zhang J, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171: 215-222.
13. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189: 280-294.